MiR-186-5p upregulation inhibits proliferation, metastasis and epithelial-to-mesenchymal transition of colorectal cancer cell by targeting ZEB1

Li, Jinlei; Xia, Limin; Zhou, Zhenhua; Zuo, Zhili; Xu, Chang; Song, Huayu; Cai, Jun

doi:10.1016/j.abb.2018.01.002

Cited by 92 publications

(77 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our data showed that BAG2 knockdown might suppress intercellular EMT process by down-regulating the expression of N-cadherin, MMP9, Vimentin and Snail, thereby reducing invasion and migration of gastric cancer cells. This is consistent with the previous results of miR186 overexpression inhibiting EMT process of cancer cells (38). In conclusion, it is suggested that the process of BAG2 promoting EMT in gastric cancer cells may be partially regulated by miR186.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

BAG2 Promotes Proliferation and Metastasis of Gastric Cancer via ERK1/2 Signaling and Partially Regulated by miR186

et al. 2020

View full text Add to dashboard Cite

Bcl2-associated athanogene (BAG)2 as a co-chaperone has been demonstrated to be involved in tumor growth and metastasis, but its biological function in gastric cancer remains unknown. Here, we reported that BAG2 was highly expressed in gastric cancer cell lines and tissues, indicating poor prognosis. High expression of BAG2 was significantly associated with T stage and differentiation level of gastric cancer (P < 0.001). Functional experiments revealed that BAG2 knockdown in gastric cancer cells inhibited the proliferation, invasion and migration of cells through AKT/mTOR and extracellular regulated kinase (ERK) pathways. Proteomic analysis identified that BAG2 may be involved in the regulation of mitogen-activated protein kinase (MAPK) pathway. In addition, immunoprecipitation showed that BAG2 could bind to ERK1/2. Luciferase reporter assay and Western blot verified that BAG2 was down-regulated by miR186. Taken together, our findings may reveal the basic function of BAG2 and uncover a potential therapeutic target for gastric cancer.

show abstract

Section: Discussionsupporting

confidence: 93%

“…EMT is a key process in tumor progression and metastasis (37). Li et al (38) showed that overexpression of miR186 inhibits metastasis and EMT of colorectal cancer cells. Zhao et al (39) found that miR186 strongly inhibits cell movement and EMT by down-regulating Twist1 in prostate cancer cells.…”

Section: Discussionmentioning

confidence: 99%

BAG2 Promotes Proliferation and Metastasis of Gastric Cancer via ERK1/2 Signaling and Partially Regulated by miR186

et al. 2020

View full text Add to dashboard Cite

show abstract

“…is theory was validated in our study and previous studies: extensive evidence had suggested that miR-186 was a tumor suppressor gene, with a downregulated expression level in cancer tissues, cells [30,31], and blood of recurrent oral squamous cell carcinoma patients compared with controls [32], including OvCa [33]. Overexpression of miR-186 into cancer cells significantly inhibited proliferation, invasion, metastasis [29,34,35], and induced mesenchymal-to-epithelial transition, G1 cell cycle arrest, and cell apoptosis [33]. STEAP2 (Seven Transmembrane Epithelial Antigen of the Prostate 2) is a gene primarily expressed in the prostate and the ovary is the only other area with a significant expression [36].…”

Section: Discussionsupporting

confidence: 78%

Recurrence‐Associated Multi‐RNA Signature to Predict Disease‐Free Survival for Ovarian Cancer Patients

Chen

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Ovarian cancer (OvCa) is an intractable gynecological malignancy due to the high recurrence rate. Several molecular biomarkers have been previously screened for early identifying patients with a high recurrence risk and poor prognosis. However, all the known studies focused on a single type of RNAs, not integrating various types. This study was to construct a new multi-RNA-based model to predict the recurrence and prognosis for OvCa patients by using the messenger RNA (mRNA, including long noncoding RNA (lncRNA)) and microRNA (miRNA) sequencing data of The Cancer Genome Atlas database. After univariate Cox regression and least absolute shrinkage and selection operator analyses, a multi-RNA-based signature (2 miRNAs: hsa-miR-508, hsa-miR-506; 1 lncRNA: TM4SF1-AS1; 11 mRNAs: MAGI3, SLAMF7, GLI2, PDK1, ARID3A, PLEKHG4B, TNFAIP8L3, C1QTNF3, NDUFAF1, CH25H, TMEM129) was generated and used to establish a risk score model. The high- and low-risk patients classified by the median risk score exhibited significantly different recurrence risks (89% versus 61%, p<0.001) and survival time (the area under the receiver operating characteristic curve (AUC) = 0.901 for 5-year disease-free survival (DFS)). This risk model was independent of other clinical features and superior to pathologic staging for DFS prediction (AUC, 0.906 versus 0.524; C-index, 0.633 versus 0.510). Furthermore, some new interaction axes were revealed to explain the possible functions of these RNAs (competing endogenous RNA: TM4SF1-AS1-miR-186-STEAP2, LINC00536-miR-508-STEAP2, LINC00475-miR-506-TMEM129; coexpression: LINC00598-PLEKHG4B). In conclusion, this multi-RNA-based risk model may be clinically useful to stratify OvCa patients with different recurrence risks and survival outcomes and included RNAs may be potential therapeutic targets.

show abstract

“…miR-186 role in colorectal cancer pathogenesis is not so clear. Some reports have identified miR-186 [5p] as a tumor suppressor due to its ability to inhibit proliferation, metastasis and EMT of colorectal cancer cells by targeting ZEB1, while others point out in the opposite direction (127)(128)(129).…”

Section: Mir-186mentioning

confidence: 99%

PVT1 Long Non-coding RNA in Gastrointestinal Cancer

2020

View full text Add to dashboard Cite

Whole genome and transcriptome sequencing technologies have led to the identification of many long non-coding RNAs (lncRNAs) and stimulated the research of their role in health and disease. LncRNAs participate in the regulation of critical signaling pathways including cell growth, motility, apoptosis, and differentiation; and their expression has been found dysregulated in human tumors. Thus, lncRNAs have emerged as new players in the initiation, maintenance and progression of tumorigenesis. PVT1 (plasmacytoma variant translocation 1) lncRNA is located on chromosomal 8q24.21, a large locus frequently amplified in human cancers and predictive of increased cancer risk in genome-wide association studies (GWAS). Combined, colorectal and gastric adenocarcinomas are the most frequent tumor malignancies and also the leading cause of cancer-related deaths worldwide. PVT1 expression is elevated in gastrointestinal tumors and correlates with poor patient prognosis. In this review, we discuss the mechanisms of action underlying PVT1 oncogenic role in colorectal and gastric cancer such as MYC upregulation, miRNA production, competitive endogenous RNA (ceRNA) function, protein stabilization, and epigenetic regulation. We also illustrate the potential role of PVT1 as prognostic biomarker and its relationship with resistance to current chemotherapeutic treatments.

show abstract

MiR-186-5p upregulation inhibits proliferation, metastasis and epithelial-to-mesenchymal transition of colorectal cancer cell by targeting ZEB1

Cited by 92 publications

References 25 publications

BAG2 Promotes Proliferation and Metastasis of Gastric Cancer via ERK1/2 Signaling and Partially Regulated by miR186

BAG2 Promotes Proliferation and Metastasis of Gastric Cancer via ERK1/2 Signaling and Partially Regulated by miR186

Recurrence‐Associated Multi‐RNA Signature to Predict Disease‐Free Survival for Ovarian Cancer Patients

PVT1 Long Non-coding RNA in Gastrointestinal Cancer

Contact Info

Product

Resources

About